Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 14 June 2026

Pharmacology

Pharmacokinetics of Peptides: Absorption, Distribution, Metabolism & Excretion

Understanding how peptides move through the body—from administration to elimination—and the strategies used to optimise their pharmacokinetic profiles for research and therapeutic applications.

Last updated: February 2026•25 min read

Introduction to Peptide Pharmacokinetics

Pharmacokinetics (PK) describes "what the body does to a drug"—how a compound is absorbed, distributed, metabolised, and eliminated. For peptides, pharmacokinetic considerations present unique challenges compared to small molecules, primarily due to their larger size, hydrophilicity, and susceptibility to enzymatic degradation.

Understanding peptide pharmacokinetics is essential for interpreting research data, understanding dosing rationales, and appreciating why certain peptide modifications have been developed. The pharmacokinetic profile directly determines how often a peptide must be administered and the peak-to-trough variability in plasma concentrations.

Why Peptide PK Matters

Research Context

• Determines timing of sample collection
• Affects interpretation of biomarker changes
• Influences study design and endpoints
• Guides dose-response relationships

Therapeutic Development

• Drives formulation decisions
• Informs dosing frequency requirements
• Identifies need for PK-enhancing modifications
• Impacts patient compliance considerations

The fundamental challenge with peptides is their rapid degradation and poor oral bioavailability. Native peptides typically have plasma half-lives measured in minutes, necessitating either frequent dosing or structural modifications to extend their duration of action.

ADME Overview

ADME—Absorption, Distribution, Metabolism, and Excretion—describes the four key pharmacokinetic processes that determine how a drug behaves in the body. Each process presents specific challenges for peptide compounds.

Absorption

Entry into systemic circulation

Distribution

Movement to tissues

Metabolism

Enzymatic breakdown

Excretion

Elimination from body

ADME Process	Peptide Challenge	Consequence
Absorption	Poor oral bioavailability (<2%)	Parenteral administration usually required
Distribution	Limited membrane permeability	Primarily extracellular distribution
Metabolism	Rapid proteolytic degradation	Short half-lives (minutes to hours)
Excretion	Renal filtration of small peptides	Additional contribution to short half-life

Absorption Challenges

Absorption refers to the process by which a peptide enters systemic circulation from its site of administration. The route of administration profoundly impacts bioavailability—the fraction of the administered dose that reaches the bloodstream in active form.

Oral Administration Barriers

Oral delivery remains the preferred route for patient convenience, yet most peptides have oral bioavailability below 1-2%. Multiple barriers prevent effective oral absorption:

Enzymatic Degradation

The gastrointestinal tract contains numerous proteolytic enzymes (pepsin, trypsin, chymotrypsin, carboxypeptidases) that rapidly cleave peptide bonds. Most peptides are degraded before reaching the intestinal epithelium.

Poor Membrane Permeability

Peptides are typically hydrophilic with multiple hydrogen bond donors/acceptors, making passive diffusion across lipid membranes extremely limited. The "Rule of 5" for oral drugs is violated.

Large Molecular Size

Paracellular transport between intestinal cells is limited to molecules under ~600 Da. Most bioactive peptides exceed this threshold, preventing this absorption route.

Efflux Transporters

P-glycoprotein and other efflux pumps actively transport peptides back into the intestinal lumen, further reducing absorption efficiency.

Routes of Administration

Route	Bioavailability	Onset	Examples
Intravenous (IV)	100% (by definition)	Immediate	Research settings, emergencies
Subcutaneous (SC)	70-100%	Minutes to hours	Insulin, GLP-1 agonists, most research peptides
Intramuscular (IM)	70-100%	Minutes	Some hormone preparations
Intranasal	10-30%	Minutes	Oxytocin, desmopressin, some neuropeptides
Oral	<2% (typically)	Hours	Oral semaglutide (with enhancer)

Subcutaneous Administration

Subcutaneous injection is the most common route for peptide administration in both research and therapeutic contexts. It offers high bioavailability, relatively slow absorption (providing a depot effect), and is practical for self-administration. Most research peptides including BPC-157, Ipamorelin, and growth hormone secretagogues are typically administered subcutaneously.

Distribution & Tissue Penetration

Once absorbed, peptides distribute throughout the body via the bloodstream. The extent and pattern of distribution depend on the peptide's physicochemical properties, protein binding, and membrane permeability.

Volume of Distribution (Vd)

Volume of distribution is a pharmacokinetic parameter describing the theoretical volume required to contain the total amount of drug at the same concentration as plasma. It indicates the extent of tissue distribution.

Vd Range	Interpretation	Peptide Examples
<0.1 L/kg	Confined to plasma (high protein binding)	Large peptides, albumin-bound
0.1-0.3 L/kg	Distributed in extracellular fluid	Most hydrophilic peptides
0.3-0.7 L/kg	Total body water distribution	Some modified peptides
>0.7 L/kg	Extensive tissue distribution	Lipophilic peptides, tissue binding

Distribution Considerations

Blood-Brain Barrier (BBB): Most peptides cannot cross the BBB, limiting CNS distribution. Exceptions include small cyclic peptides and those with specific transport mechanisms. Intranasal delivery may partially bypass the BBB for some neuropeptides.
Protein Binding: Binding to plasma proteins (albumin, α1-acid glycoprotein) can serve as a reservoir, prolonging half-life but reducing free (active) concentration. Lipidated peptides exploit albumin binding for PK enhancement.
Receptor-Mediated Uptake: Some peptides undergo receptor-mediated endocytosis in target tissues, concentrating the peptide at sites of action and contributing to clearance.

Metabolism & Degradation

Peptide metabolism differs fundamentally from small molecule metabolism. Rather than hepatic cytochrome P450-mediated oxidation, peptides are primarily degraded by proteolytic enzymes (peptidases) found throughout the body. This has important implications for drug interactions and metabolite formation.

Peptidase Classes

Enzyme Class	Cleavage Site	Location	Examples
Aminopeptidases	N-terminus	Plasma, tissues, cell surface	Aminopeptidase N (CD13)
Carboxypeptidases	C-terminus	Plasma, pancreas, tissues	Carboxypeptidase A, B, E
Endopeptidases	Internal peptide bonds	Widespread	Neprilysin (NEP), ACE
Dipeptidyl peptidases	N-terminal dipeptide	Cell surface, plasma	DPP-4 (inactivates GLP-1)

DPP-4 and Incretin Metabolism

Dipeptidyl peptidase-4 (DPP-4) is particularly important for incretin peptides. Native GLP-1 has a half-life of only 1-2 minutes due to rapid DPP-4 cleavage. This has driven the development of:

• DPP-4 inhibitors (gliptins) – protect endogenous GLP-1
• DPP-4 resistant GLP-1 analogues – amino acid substitutions at position 2
• Long-acting GLP-1 agonists – combine DPP-4 resistance with albumin binding

Why Peptides Degrade Faster Than Small Molecules

Peptides

• Multiple cleavage sites (each peptide bond)
• Ubiquitous peptidases in plasma & tissues
• Evolved to be rapidly regulated
• No phase I/II metabolism required
• Products are natural amino acids

Small Molecules

• Limited metabolic sites
• Primarily hepatic metabolism (CYP450)
• Often require bioactivation
• Phase I → Phase II conjugation
• May produce active/toxic metabolites

Excretion Pathways

Peptide excretion occurs primarily through renal elimination, with the kidneys filtering small peptides and their metabolites from the blood. The contribution of renal excretion to overall clearance depends on peptide size and protein binding.

Renal Handling of Peptides

1
Glomerular Filtration: Peptides under ~30 kDa are freely filtered at the glomerulus. Larger peptides and those bound to plasma proteins are retained.
2
Tubular Reabsorption: Small peptides may be reabsorbed via peptide transporters (PEPT1, PEPT2) in proximal tubules, followed by intracellular hydrolysis.
3
Peritubular Uptake: Receptor-mediated endocytosis via megalin/cubilin complexes captures peptides from peritubular blood for degradation.
4
Urinary Excretion: Intact peptide excretion in urine is typically minimal; most are degraded to amino acids that are recycled.

Clinical Note: Renal impairment can significantly affect peptide pharmacokinetics. Reduced renal clearance may necessitate dose adjustments, particularly for peptides where the kidney contributes substantially to elimination (e.g., insulin, exenatide).

Half-Life & Dosing Frequency

Half-life (t½) is the time required for plasma concentration to decrease by 50%. It determines how frequently a peptide must be administered to maintain therapeutic levels and is a critical parameter in peptide development.

Peptide	Half-Life	Typical Dosing	Key Factor
Native GLP-1	1-2 minutes	Continuous infusion (research only)	Rapid DPP-4 cleavage
Exenatide	2.4 hours	Twice daily	DPP-4 resistance
Liraglutide	13 hours	Once daily	Albumin binding
Semaglutide	~7 days	Once weekly	Enhanced albumin binding
GHRH (native)	~7 minutes	Pulsatile (research)	Rapid proteolysis
Ipamorelin	~2 hours	Multiple daily (research)	Moderate stability
CJC-1295 DAC	~6-8 days	Once weekly (research)	Drug Affinity Complex (DAC)

Half-Life Considerations

Advantages of Longer Half-Life

• Less frequent dosing
• Better compliance
• Smoother plasma concentrations
• Reduced peak-related side effects

Advantages of Shorter Half-Life

• More physiological pulsatile patterns
• Rapid clearance if adverse effects
• Flexible timing around meals/activity
• Reduced receptor desensitisation

Modifications to Extend Half-Life

Various strategies have been developed to overcome the inherent pharmacokinetic limitations of peptides. These modifications can dramatically extend half-life while preserving biological activity.

PEGylation

Attachment of polyethylene glycol (PEG) chains to peptides increases hydrodynamic radius, reducing renal filtration and proteolytic access.

Advantages

• Significantly extended half-life
• Reduced immunogenicity
• Well-established technology

Considerations

• May reduce potency
• PEG accumulation concerns
• Anti-PEG antibodies possible

Lipidation (Fatty Acid Acylation)

Attachment of fatty acid chains (e.g., palmitic acid) enables non-covalent binding to serum albumin, creating a circulating reservoir that slowly releases active peptide.

Example: Semaglutide

A C18 diacid chain is attached via a spacer to position 26 of GLP-1. Combined with amino acid substitutions, this achieves a ~7-day half-life enabling once-weekly dosing. This approach revolutionised GLP-1 therapy convenience.

Fc Fusion

Fusion with the Fc region of IgG antibodies exploits the neonatal Fc receptor (FcRn) recycling pathway, dramatically extending half-life.

Example: Dulaglutide (GLP-1-Fc fusion) has a half-life of approximately 5 days, enabling once-weekly dosing.

Amino Acid Modifications

Strategic substitution of natural L-amino acids with:

D-amino acids: Resistant to most L-specific proteases
N-methylation: Blocks peptidase recognition and enhances membrane permeability
Unnatural amino acids: Designer residues that resist enzymatic cleavage
Cyclisation: Head-to-tail or side-chain cyclisation removes vulnerable termini

Drug Affinity Complex (DAC)

A proprietary technology that promotes covalent binding to serum albumin following injection, creating a long-lasting depot.

Example: CJC-1295 DAC uses maleimidopropionic acid to achieve albumin binding, extending half-life from ~30 minutes (CJC-1295 without DAC) to approximately 6-8 days.